Antimicrobial Guidelines for Urinary Tract Infections- ICMR
Urinary tract infection (UTI) is one of the common community acquired infections and is seen more commonly in females.
Indian Council of Medical Research, Department of Health Research has issued the Antimicrobial Guidelines for Urinary Tract Infections. Following are the major recommendations :
Definition: Infections of the urinary tract caused by pathogens consistent with the clinical picture
Divide as
Anatomy
- Upper UTI –Pyelonephritis
- Lower UTI – Cystitis
Clinical syndrome
- Asymptomatic bacteruria
- Symptomatic bacteruria
- Pyelonephritis
CAUTI in catheterized/ hospitalized/complicated cases the management has to be done based on the specific situations ( more details are discussed in section on device associated infections)
Common pathogens:
E. coli is responsible for about 80-90% of UTI in the community. This is followed by Proteus sp., Klebsiella sp., Staphylococcus aureus, etc. Staphylococcus saprophyticus causes infection in young women in many countries but this is rare in India.
In hospital acquired UTIs or in the presence of devices, Pseudomonas aeruginosa, Acinetobacter sp, Enterococci etc., are causative agents depending on the setting. In patients on long term catheters and antibiotic therapy, Candida sp is also implicated.
Investigations
Urine Specimen
- Clean catch mid stream- most common and convenient
- Suprapubic aspirate- only in cases of small children where voided urine is difficult to collect or in adults in case diagnosis is not getting confirmed by voided specimen.
Transport of specimen
Urine specimen must be transported as early as possible. For up to 4 hours delay, the urine should be refrigerated. But it is unsuitable beyond that time when 0.8% boric acid as preservative can be used to store urine for up to 24 hours if transported from distance.
Examination
- Direct Microscopy- Pus cells, RBC, Casts etc.
- Rapid- Presence of pus cells by leucocyte esterase/nitrate reduction tests.
- Culture- Semiquantitare culture for determining significant counts.
Bacterial Culture
It is the gold standard and is done by semi quantitative culture. The diagnosis is based on the presence of "significant bacterial" counts in the urine specimen. Urine is otherwise a sterile fluid in the bladder but during the passage through the urethra can get contaminated with perineal flora colonizing the lower urethra. A count of 105 bacteria/ml of urine in a clean catch mid stream specimen is "Significant bacteriuria" in a person with symptoms of the lower urinary tract like dysuria, frequency, suprapubic pain and hematuria.
On a urine microscopy, pus cells > 10,000/ml along with positivity for nitrite or leucocyte esterase in a symptomatic individual indicates probable UTI. In children commonly, one bacteria per oil immersion field in an uncentrifuged urine sample is considered a possible indication of a UTI. Rarely due to the inflammation red blood cells may be present and thus falsely increase the number of pus cells.
Even if urine microscopy or urine cultures are not indicative of a UTI, caution should be exercised in case of obstructive uropathy, patient on antibiotics, hematogenous route of infection, in suprapubic aspirate specimen if the patient is clearly symptomatic..
In children suprapubic aspirate may be needed due to the problem in collecting an appropriate specimen. Any count in this sample is considered significant.
Recurrent UTIs may suggest an underlying anatomic abnormality and a urological evaluation with contrast imaging may be required for delineation of the same.
Prevalent Resistance
E. coli and other members of family Enterobacteriaceae remain the most common cause of UTI, however antimicrobial resistance is very high to the commonly prescribed antibiotics in various Indian studies and the ICMR AMR network data (Table). Most Enterobacteriaceae isolates are ESBL or extended spectrum betalactamase producing curbing the utility of 3rd and 4th generation cephalosporins and most beta lactam antibiotics. Most often we have to resort to Carbapenems.
Table 1. Antimicrobial Susceptibility of Enterobacteriaceae isolates from urinary tract. ICMR, AMRSN data 2014.
Note : Ec : E. coli ; Ks : Klebsiella sp. : Es : Enterobacter sp.
Table2 : Treatment regimens for urinary tract infections
Clinical Condition | Common Pathogens | Empiric AMA | Alternate AMA | Comments |
Acute Cystitis (in absence of cultures) | E.coli, Proteus sp Klebsiella sp. | ●Nitrofurantoin 100 mg BD for 7 days ●Cotrimoxazole 500/125 mg BD for 3-5 days ●Ciprofloxacin 500 mg BD for 3-5 days | ●Cefuroxime 250 mg BD for 3-5 days ● Cefixime 400mg BD for 5 days | Staphylococcus saprophyticus (in sexually active young women) but is not common in India. In pregnancy the duration of treatment is longer |
Acute Pyelonephritis (individualized based on data from each center) If blood culture is positive, a carbapenem is preferred) | E.coli, Klebsiella sp Proteus sp S. aureus | ●Piperacillin tazobactam 4.5 gm IV 6 hourly for 10 days ● Ertapenem 1 g IV OD for 7 days | ●Imipenem 500 mg IV 8 hourly for 10 days or ●Inj Amikacin 5mg/kg IV once daily x 10 days | Urine and blood culture should be done before start of treatment. Amikacin 1gm OD IV or Gentamicin 7 mg/kg as prescribed doses . Close monitor on renal parameters is needed and watch out for relapse |
Acute prostatitis | Enterobacteri aceae (E. coli, Klebsiella sp.) | ●Doxycycline 100 mg BD for 2-3 wks ●Co-trimoxazole 960 mg BD for 2-3 wks Ciprofloxacin 500 mg BD for 2-3 wks | ●Piperacillin tazobactam 4.5 gm IV 6 hourly ●Cefoperazone sulbactam 3 gm IV 12 hourly ● Ertapenem 1 gm IV OD or Imipenem 1 gm IV 8 hourly or Meropenem 1 gm IV 8 hourly | Get urine and prostatic massage cultures before antibiotics. Treatment may be needed for longer duration |
All these regimens need to be tailored according to susceptibility patterns at individual centers
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd